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• Novel Contrast Agent Targeted to Ultrasonic 
D-Dlmer Using DD-3B6 Monoclonal F(ab) In Vitro 
Gregory M. Lanza, Kirk D. Wallace, Paul R. Eisenberg, Michael J. Scott, 
William P. Cscherls, Donald H. Christy, Angola M. Sharkey, James G. Miller, 
Samuel A. Widdine. JeR~sh And Barnes Hospi;als M Washington University, 
St. Louis, MO 
To facilitate sensitive and specific detection of vascular thromboses, we have 
recently developed a targatable uitrasonio contrast agent (nongaseous, bi- 
otinylated lipid encapsulated perftuoroceeban emulsion, moan particle size 
250 nm) that permits noninvasive detection of fibdn clots by binding to molec- 
ular ligands associated with thrombi and enhancing acoustic rallectivity. The 
targeted ultrasonic ontrast agent was prepared by biotinylating the fluorocar- 
bon emulsion particles. To mimic small, suspended, ameslinked fibrin thrombi, 
D-dimer was coated directly onto 0.8/~ palystyreno beads and ultrasonically 
imaged w,'th a 7.5 MHz linear phased army before and after eR)osure to the 
ligand-tergeted contrast agent. The polystyrene particles appeared opaque 
within dialysis tubing but manifested little ultrasonic backscefter. Sequen- 
tial addition of a biotinylaled monocional F(~) fragment directedagainst the 
D-dimer epRope 3B6, followed by aviclin, followed by biotinylated acoustic 
contrast rapidly increased the echogeniolty of the suspension. To mimic sur- 
face adherent, crossiinked flbdn thrombus, D-direst was covalently bound 
to nilrocelluluse membranes and ultrasonic imaging was performed before 
and after targeting with the parfluorocarbon emulsion with a high resolution, 
broadband 50 MHz acoustic microscope. The targeted ultrasonic ontrast in- 
creased the backscatter of the nitrocellulose membranes at all frequendes 
between 50 and 60 MHz, by an average 4.6 4- 0.1 dB (p < 0.05) above con- 
trois (2.9 fold enhancement). These results demonstrate th~ potential of this 
novel, site-targeted pertluorocarbon ultrasonic ontrast agent o specifically 
bind to molecular epitopes in fibdn clots, enhance their acoustic reflectlvity, 
and suggest a clinical role for clot detection with the use of ultrasound. 
~ Io Five-Year Morlality by Different for  Treatment 
Choice vs. Random Assignment In the Bypass 
Angioplasty Revasculadzstlon Invssti~atlan 
(BARI)? 
Katherine Detre, Nlan Rosen, Robert Jones, William Rogers, Michael Mock, 
David Faxon, Martial Bourasse, Frodedck Feit, Michael Cowley, Floy~ Loop 
aqd the BARI Investigators. University of Pittsburgh, Pittsburgh, PA 
BARI recruited 4110 patients with multivessal coronary artery disease mqt~ir- 
ing revascularlzation who were suitable for either CABG or PTCA. Consent 
for random treatment assignment was obtained from 1829 patients; another 
2013 preselVed the right to chose their treatment but agreed to be fogowed 
in a registry, and 268 refused to participate. W'dhin 3 months of study enW, 
CABG was the initial procedure for 32% of registry patients, PTCA for 58%, 
and the remaining 10% were maintained on medication only. 
Tx by Random Assignment Tx by Choice 
Age > 65 39% 40% 
Female 27% 26% 
African American 6% 4% 
Post HS Education 29% 40% 
Pmx/MId LAD 76% 69% 
# Lesion • 50% 3.1 3.0 
% Myocardium Jeopardized 61.1 59.2 
Hx MI 55% 51% 
Hx CHF 0% 5% 
Unstable Angina 64% 61% 
The 5-year mortality for patients in the BARI trial will be compared to the 
BARI registry adjusting for differences in patient charactodstics between the 
groups. 
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~ N e w  Ganeti© Coronary Artery Risk Factors for  
Disease 
Madsa Serrato, Qun-Tao Yu, Feye Safavi, Robert Roberts, All J. Marian. 
Baylor College of I~dicine, Houston, Texas 
Coronary artery disease (CAD) is a complex lrait caused by a number of ge- 
netic and environmental factors. Techniques of molecular genetics provide 
the opportunity to identify genes that may confer increased susceptibility 
for CAD. Human pareoxoneae/arylesterase (HUMPONA), involved in oxi- 
dation of LDL cholesterol, ~-fibdnogen, necessary for thrombosis, and the 
rantn angiotenaln system (anglotensinogan (AGT), angiotensin II receptor I
(ATIIRla)), which induces cell proliferation, are all involved in athemsclero- 
sis. Variants of these genes am known to encode for proteins that enhance 
their raspective function and am, thus, potential candidate genes for al- 
tered susceptibility to atherosclerosis. Thus, we determined the frequency 
of these variants in a genetically homogenous population with angiographi- 
celly documented CAD and in a comparable group in the general population. 
DNA was extracted from the blood and ganotyges were determined by poly- 
merase chain reaction, gel electrophoreais and/or mstricUon mapping. The 
two variants of AGT (M235T, T174M) and that of ATilRla exhibited asimilar 
frequency in both groups, while that of HUMPONA (G92A) and p-fibdnogen 
(G/A "4ss) showed increased frequency in the group with CAD as shown in 
the Table. 
Genotypes Control CAD Odds Ratio P value 
HUMPONA (GgP.A) 
/VA 120 (49%) 68 (30%) 2.2 (1.5-3.1) <0.CO01 
A/G + G/G 127(51%) 15S (70%) 
p Fibdnogen (G/A "4ss) 
G/G 153 (54%) 135 (75%) 2.5 (1.7-3.8) <0.0001 
G/A+/VA - 130(46%) 46(25%) 
The protein product of the HUMPONAgena variant is known to increase the 
rate of oxidation of LDL cholesterol several-fold and the p-fibdnogen variant 
is known to be associated with increased plasma levels of fibdnogen, both of 
which provide a rationale for increased risk of CAD and coronmy thrombosis. 
Identification and characterization fnonconventional genetic dsk factors for 
CAD will provide not only insight into the pathogenesis of athersclerosis but 
also dsk stmtif'cation for improved prevention and tmatmanL 
~ Circulating Correlates W'dh the Extent of VCAM-1 
Human Atherosclerosis, in Contrast to Circulating 
ICAM-1, E-selactin and Thrombomodulin 
Karlhei,'lz Peter, Peter Nawroth, Wolfram SchLsf, Thomas Nordt, 
Thomas Weiss, Christoph Bode. University of Heidelberg, Germany 
Secondary prevention of alheroealerosis, pdor to causing clinical symptoms, 
could be poss~e with a serum marker for atherosclerosis. Circulating, shed- 
dad forms of adhesion molecules may sere as such, since the cell surface 
expression of adhesion molecules is upragulated on endothelial cells cover- 
ing ab'~roscierotic plaques. In 52 patients with peripheral artedal vascular 
disease the extent of atherosclemsis was evaluated based on angiograms 
of a large par,on of the arterial system (the abdominal aorta, the pelvic and 
lag artadas). The area diseased by atheroscleresis was determined by the 
percentage of vessel wall irregularities of the calculated segments (total: 250 
cng). 
The serum concentration of circulating VCAM-1 demonstrates a strong 
correlation to the extent of atheroscierosis (r= 0.8, p < 0.001, y = 7.3x ng/ml 
cm -2 + 294 ng/ml), in contrast o circulating ICAM-1, E-selectin, or throm- 
bomodulin (as a marker for endothelial cell damage). The angiogrsphically 
evaluated patients were ~ in a group with minor (n = 30, area < 90 cn~) 
and a group with major atharesclerotic changes (n = 22, area > 90 cm2). The 
serum level of circulating VCAM-1 allows to separate these two stages of 
atharesclerosas with a high st:itistical significance (623 + 157 ng/ml versus 
1238:1:528 ngtml, p < 0.001). 
Condus/ons: Circulating VCAM-1 demanstmtes a strong correlation to 
the extent of human atherosclerosis. Whether patients who will profit from 
agreasive diagnosis and troalment can be identified by increased levels of 
circulating VCAM-1 remains to be proven. 
~ Prssence and Distribution of Vascular Wall 
Adrenomedullln in Experimental Atherosclarosla 
Eric E. Williamson, Michihisa Jougasaki, Iftikher Kugo, John C. Bumeft Jr.. 
Mayo Clinic, Rochester, MN 
Adrenomedugin (ADM) is a newly discovered potent vasorelaxant peptide, 
recently demonstrated tobe synthesized by cuitured endothelial end vascu- 
lar smooth muscle coils. Although ADM may function as an autocdne and 
paracdne factor in cardmvascular homeostasis, its activity in disease states 
such as atheroscierosis has not been defined. The present study was per- 
formed to determine the presence and distribution of ADM in normal and 
atherosclemtio rabbit aorta by imruunohistechemistry utilizing a highly spe- 
cific antg0edy to rabbit ADM. Studies were designed to test the hypothesis that 
ADM is present in normal aortic endothelial nd vascular smooth muscle ceils 
and is increased in atherosclerosis nresponse to vascular wall injury. To test 
this hypothesis, aortic tissue was obtained from normal (n -- 4) and cholesterol 
fed rebi)its (n = 14) (1% cholesterol diet for 8-10 weeks). In normal coutxo| 
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